Goszcz A, Grodzińska L, Kostka-Trabka E, Bieroń K, Sławiński M, Jachym R, Ochmański W
Katedry Farmakologii, Zakładu Farmakologii Klinicznej Collegium Medicum, Uniwersytetu Jagiellońskiego w Krakowie.
Przegl Lek. 1997;54(7-8):505-9.
Misoprostol, the oral analogue of alprostadil was used for the treatment of 20 patients (aged 40-60) with peripheral arterial disease according to Fontaine's classification at stages IIa and IIb (PAD). All patients received 200 micrograms of misoprostol 3 times a day during a month. The therapy with misoprostol resulted in a clinical improvement in all patients. Elongation of pain free (before treatment 129 m +/- 78 m, after treatment 214 m +/- 109 m) and maximum walking distance (before treatment 304 m +/- 169 m, after treatment 471 m +/- 264 m) was observed. At the same time a shortening of the pain duration was noted (before treatment 100 sec +/- 37 sec, after treatment 71 sec +/- 23 sec). The ankle/arm pressure ratio (AAPR) and arterial blood flow increased in both limbs after 4 weeks of the treatment. Activation of the fibrinolytic system was seen in the course of the therapy (shortening of euglobulin clot lysis time-ECLT and increase in t-PA activity). The platelets became less sensitive to ADP and collagen after intake of misoprostol. The results justify administration of misoprostol as a new therapeutic agent for the treatment of patients with PAD.
米索前列醇是前列地尔的口服类似物，根据Fontaine分类法，用于治疗20例年龄在40至60岁之间处于IIa期和IIb期的外周动脉疾病（PAD）患者。所有患者在一个月内每天服用3次200微克米索前列醇。米索前列醇治疗使所有患者的临床症状得到改善。观察到无痛行走距离延长（治疗前129米±78米，治疗后214米±109米）和最大行走距离延长（治疗前304米±169米，治疗后471米±264米）。同时，疼痛持续时间缩短（治疗前100秒±37秒，治疗后71秒±23秒）。治疗4周后，双下肢的踝/臂压力比（AAPR）和动脉血流增加。在治疗过程中观察到纤维蛋白溶解系统的激活（优球蛋白凝块溶解时间缩短-ECLT和组织型纤溶酶原激活物活性增加）。服用米索前列醇后，血小板对ADP和胶原蛋白的敏感性降低。这些结果证明米索前列醇可作为治疗PAD患者的一种新的治疗药物。
